Are new cancer treatments improving survival or quality of life?
This is the question that a recent study in BMJ by Davis et al. (2017) attempts to answer. They use data from 48 cancer drugs for 68 indications that were approved by the European Medicines Agency (EMA) between 2009 and 2013. Among these 68 indications, they found that: only 35 (51%) were associated with significant improvement…